International Cancer Conference Journal最新文献

{"title":"A case of ER-positive, HER2-negative metastatic breast cancer with high tumor mutation burden achieving complete response to pembrolizumab monotherapy.","authors":"Akihiro Umejima, Nobuko Kawaguchi-Sakita, Yosuke Yamada, Kosuke Kawaguchi, Masahiro Kawashima, Masahiro Takada, Chiaki Suzuki, Yukiko Mori, Masahiro Yoshioka, Masashi Kanai, Manabu Muto, Masakazu Toi","doi":"10.1007/s13691-026-00871-5","DOIUrl":"10.1007/s13691-026-00871-5","url":null,"abstract":"<p><p>Comprehensive genomic profiling can identify actionable mutations and guide therapy selection in metastatic breast cancer. Tumor mutation burden (TMB) may predict response to immune checkpoint inhibitor (ICI) therapy, but its clinical utility in estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer remains unclear. In this case report, we describe a 63-year-old woman with ER-positive, HER2-negative metastatic breast cancer who had exhausted standard treatment options. Comprehensive genomic profiling of the pancreatic metastatic tissue revealed a TMB of 33 mutations per megabase (mut/Mb), consistent with TMB-high status. Based on this result, pembrolizumab therapy was initiated in October 2022. Subsequent imaging demonstrated a complete response, with disappearance of FDG uptake in the pancreatic, renal, and lung metastases on positron emission tomography/computed tomography (PET/CT). Tumor marker levels also normalized, and this response has been maintained as of January 2026. This case highlights the potential utility of TMB-high status as a predictive biomarker for ICI therapy in ER-positive, HER2-negative metastatic breast cancer. Although this subtype is typically considered less immunogenic, TMB-high may identify patients who could benefit from immune checkpoint blockade. Comprehensive genomic profiling should be considered when standard treatments are limited.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"15 3","pages":"399-403"},"PeriodicalIF":0.4,"publicationDate":"2026-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13376100/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148578298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Duodenal metastasis of hepatocellular carcinoma following multimodal therapy: a rare case report and literature review.","authors":"Nobuhisa Tanioka, Satoru Seo, Kohei Araki, Kazune Fujisawa, Masaya Munekage, Hiromichi Maeda, Hiroyuki Kitagawa, Tsunehiro Ochi, Mitsunari Ogasawara, Akira Hirose","doi":"10.1007/s13691-026-00872-4","DOIUrl":"10.1007/s13691-026-00872-4","url":null,"abstract":"<p><p>We present a rare case of duodenal metastasis of hepatocellular carcinoma (HCC) following multimodal therapy, in which the patient died shortly after the palliative surgical intervention. An 80-year-old man with HCC associated with chronic hepatitis B was admitted to our emergency department owing to complaints of anorexia and vomiting. He had undergone conversion surgery following systemic therapy that included a multikinase inhibitor and immune checkpoint inhibitors. Three months prior, transcatheter arterial chemoembolization and radiofrequency ablation had been performed for two intrahepatic recurrences. Contrast-enhanced abdominal computed tomography and upper gastrointestinal endoscopy revealed multiple intrahepatic recurrences, pulmonary metastases, and duodenal metastasis of HCC. Following the resolution of obstructive jaundice, the patient underwent palliative gastrojejunostomy. His postoperative course was complicated by progressive renal dysfunction and coagulopathy, and he died on postoperative day 15. In the literature review, including this case, 61 patients with duodenal involvement of HCC were identified. Although a small subset of patients achieved long-term survival after curative-intent surgery performed under highly selective conditions, the overall life expectancy for most patients remained poor. Even with palliative intent, surgical intervention for unresectable duodenal involvement caused by HCC should be pursued with careful consideration of the patient's prognosis and systemic condition.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"15 3","pages":"404-412"},"PeriodicalIF":0.4,"publicationDate":"2026-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13376109/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148578501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pulmonary tumor thrombotic microangiopathy associated with prostate cancer achieving over 10-year survival: a case report.","authors":"Masanari Nishida, Masayuki Nagasawa, Yuji Sakano, Eiki Hanada, Akinori Wada, Tetsuya Yoshida, Susumu Kageyama","doi":"10.1007/s13691-026-00875-1","DOIUrl":"10.1007/s13691-026-00875-1","url":null,"abstract":"<p><p>Pulmonary tumor thrombotic microangiopathy (PTTM) is a rare and often fatal pulmonary complication of malignancy, characterized by rapidly progressive pulmonary hypertension and difficulty in ante-mortem diagnosis. We report a case of PTTM associated with previously untreated metastatic prostate cancer in a 62-year-old man with an initial serum prostate-specific antigen level of 3,835 ng/mL and clinical stage cT3N0M1. ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) performed during the diagnostic workup revealed findings suggestive of pulmonary hypertension and right heart strain before the onset of overt respiratory failure. Shortly after prostate biopsy, the patient developed acute hypoxemic respiratory failure. Based on the clinical suspicion of PTTM, hormonal therapy was initiated promptly before pathological confirmation, resulting in rapid improvement of respiratory status. A definitive diagnosis of PTTM was subsequently established by pulmonary artery aspiration cytology obtained via right heart catheterization. The patient has remained alive for more than 10 years without recurrence of PTTM. This appears to represent the longest survival reported for PTTM to date. This case highlights the importance of early clinical suspicion and prompt cancer-directed therapy in patients with suspected PTTM.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"15 3","pages":"427-432"},"PeriodicalIF":0.4,"publicationDate":"2026-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13376083/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148578479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune checkpoint inhibitor-associated uveitis in a patient with breast cancer and a remote history of Vogt-Koyanagi-Harada disease: a case report.","authors":"Konoka Uraguchi, Kanako Saito, Kumiko Kato, Rena Yamakado, Akira Tsunoda, Hiroki Oka, Yasutaka Tono, Kosuke Kawaguchi, Isao Tawara, Toshiro Mizuno","doi":"10.1007/s13691-026-00873-3","DOIUrl":"10.1007/s13691-026-00873-3","url":null,"abstract":"<p><p>Immune checkpoint inhibitors (ICIs) have demonstrated substantial efficacy in the treatment of triple-negative breast cancer (TNBC). However, appropriate management of immune-related adverse events (irAEs) remains essential, and patients with a history of autoimmune disease have an increased risk of developing irAEs. Immune-related uveitis represents an uncommon irAE overall and has been reported most frequently in melanoma, whereas reports among patients with BC remain rare. We describe a case of ICI-associated uveitis occurring shortly after treatment initiation in a patient with a very remote history of autoimmune uveitis. A woman in her 50s with locally advanced TNBC (cT4bN0M0, stage IIIB) and a history of Vogt-Koyanagi-Harada disease-associated uveitis in complete remission for more than 25 years received neoadjuvant chemotherapy combined with pembrolizumab. Three weeks after initiation, decreased visual acuity developed in the left eye, and grade 2 uveitis was diagnosed as an irAE. Pembrolizumab was discontinued, and systemic corticosteroid therapy was initiated, resulting in early ophthalmic improvement. Subsequently, Stevens-Johnson syndrome developed after prophylactic trimethoprim-sulfamethoxazole administration, necessitating steroid pulse therapy and high-dose intravenous immunoglobulin, after which the uveitis completely resolved. Neoadjuvant chemotherapy was continued without pembrolizumab, followed by mastectomy, which revealed ypT1aN0 disease. At 2 years of follow-up, the patient remains disease-free without recurrence of uveitis. This case indicates that a remote history of autoimmune uveitis may represent a risk factor for ICI-associated uveitis, supporting the need for careful pretreatment assessment, vigilant monitoring, and close collaboration with ophthalmologists.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"15 3","pages":"413-421"},"PeriodicalIF":0.4,"publicationDate":"2026-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13376084/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148578470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical utility of diagnostic laparoscopy for ovarian metastasis from breast cancer in a <i>BRCA1</i>-mutated patient with hereditary breast and ovarian cancer syndrome: a case report and literature review.","authors":"Sho Sato, Mitsumasa Osakabe, Shingo Hosomi, Ayaka Kitamura, Nanako Jonai, Shun Takagi, Kazuyuki Murakami, Eriko Takatori, Yoshitaka Kaido, Hiroki Onoue, Takayuki Nagasawa, Masahiro Kagabu, Naoki Yanagawa, Tadahiro Shoji, Tsukasa Baba","doi":"10.1007/s13691-026-00869-z","DOIUrl":"10.1007/s13691-026-00869-z","url":null,"abstract":"<p><p>Ovarian metastasis from breast cancer has been reported in a substantial number of cases; however, reports that specifically document ovarian metastasis in the setting of hereditary breast and ovarian cancer syndrome remain limited. We describe a woman in her forties with hereditary breast and ovarian cancer syndrome caused by a germline <i>BRCA1</i> mutation (c.117_118del) and a history of left-sided triple-negative breast cancer, invasive ductal carcinoma, clinical stage T1cN1M0, treated with mastectomy, adjuvant dose-dense epirubicin/cyclophosphamide and paclitaxel, followed by one year of maintenance therapy with olaparib. Two months after completion of olaparib, surveillance imaging identified bilateral ovarian masses with marked fluorodeoxyglucose uptake, peritoneal dissemination, and para-aortic lymph node enlargement, with elevated cancer antigen-125. Diagnostic laparoscopy with bilateral salpingo-oophorectomy revealed yellow serous ascites and multiple peritoneal nodules. Both ovarian tumors showed adenocarcinoma composed of small nests and cords. Sections prepared using the Sectioning and Extensively Examining the Fimbrial End protocol showed no serous tubal intraepithelial carcinoma. Immunohistochemical staining revealed CK7 and GATA3 expression, but no CK20, PAX8, WT-1, AR, ER, PgR, or HER2 expression. These results support a diagnosis of ovarian metastasis from the patient's prior triple-negative breast cancer. Cytologic examination of ascitic fluid was negative for malignant cells. This case highlights that, in patients with hereditary breast and ovarian cancer syndrome and a history of breast cancer who present with ovarian tumors, both primary ovarian cancer and metastatic breast cancer should be considered. Diagnostic laparoscopy with pathologic and immunohistochemical evaluation provides a definitive diagnosis, helps avoid unnecessary cytoreductive ovarian cancer surgery, and supports timely initiation of breast cancer-directed systemic therapy.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s13691-026-00869-z.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"15 3","pages":"387-394"},"PeriodicalIF":0.4,"publicationDate":"2026-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13375985/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148578472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acinic cell carcinoma of the breast in a patient with a <i>BRCA1</i> pathogenic variant: a case report.","authors":"Nanako Fujishima, Naoko Iwamoto, Shin-Ichiro Horiguchi, Takuhiko Inokuchi, Takashi Kuwayama","doi":"10.1007/s13691-026-00870-6","DOIUrl":"10.1007/s13691-026-00870-6","url":null,"abstract":"<p><p>Acinic cell carcinoma (ACC) of the breast is a rare subtype of breast cancer, and its clinicopathological and molecular characteristics remain poorly understood. We report a case of breast ACC detected through pathological examination of a risk-reducing mastectomy (RRM) specimen in a carrier of a <i>BRCA1</i> pathogenic variant. The patient was a woman in her 30s who underwent neoadjuvant chemotherapy for right-sided breast cancer, followed by right total mastectomy and contralateral RRM. Histopathological evaluation of the RRM specimen revealed ACC of the breast. No adjuvant therapy was administered, and the patient has remained disease-free for two years after surgery. Reports of breast ACC associated with <i>BRCA1</i> pathogenic variants are limited. This case highlights the extreme rarity of breast acinic cell carcinoma occurring in <i>BRCA1</i> pathogenic variant carriers and emphasizes the need for further case accumulation to clarify its clinicopathological features and potential genetic background.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"15 3","pages":"395-398"},"PeriodicalIF":0.4,"publicationDate":"2026-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13376106/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148578487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiation-induced myocardial metabolic impairment detected by ¹²³I-BMIPP/⁹⁹ᵐTc-MIBI metabolic-perfusion mismatch following thoracic radiotherapy for thymoma: a case report.","authors":"Masaki Watanabe, Yaichiro Hashimoto, Maiko Sone, Kyoko Oguri, Sakura Nishiwaki, Michinobu Nagao, Shuji Sakai","doi":"10.1007/s13691-026-00868-0","DOIUrl":"10.1007/s13691-026-00868-0","url":null,"abstract":"<p><p>Radiation-induced heart disease is a well-recognized late complication of thoracic radiotherapy and comprises a broad spectrum of cardiac disorders. Because myocardial metabolic impairment may precede overt structural or perfusion abnormalities, early or subclinical myocardial injury is often challenging to detect using conventional cardiac imaging modalities. We report a case of late-onset radiation-induced myocardial metabolic impairment identified by dual myocardial scintigraphy many years after thoracic radiotherapy for thymoma. The patient, a man diagnosed with malignant thymoma at 42 years of age, underwent two courses of thoracic radiotherapy during the course of his illness. The first course was confined to the mediastinum without cardiac exposure, whereas the second course, delivered at 52 years of age for recurrent disease with pericardial and myocardial invasion, resulted in direct cardiac irradiation. After a prolonged asymptomatic period, at 67 years of age (approximately 15 years after the second course of radiotherapy), the patient developed symptoms consistent with heart failure. Coronary angiography revealed no significant coronary artery stenosis. Dual myocardial scintigraphy demonstrated a characteristic metabolic-perfusion mismatch: reduced uptake of ¹²³I-β-methyl-p-iodophenyl-pentadecanoic acid (BMIPP) in the anterior to lateral wall of the left ventricle, precisely corresponding to the irradiated cardiac region, while myocardial perfusion assessed by ⁹⁹ᵐTc-methoxyisobutylisonitrile (MIBI) was preserved. Retrospective dosimetric analysis demonstrated a mean heart dose of 12.8 Gy during the second course of radiotherapy, supporting a radiation-induced mechanism of myocardial impairment. This case highlights the clinical value of combined ¹²³I-BMIPP and ⁹⁹ᵐTc-MIBI myocardial scintigraphy for the noninvasive detection of late-onset radiation-induced myocardial impairment in long-term cancer survivors, even in the absence of obstructive coronary artery disease.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"15 3","pages":"381-386"},"PeriodicalIF":0.4,"publicationDate":"2026-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13376271/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148578456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adenocarcinoma with endometrioid features originating in the male genitourinary tract after hormonal therapy for prostate cancer.","authors":"Sayaka Kimoto, Kei Daizumoto, Tomoko Kobayashi, Ryotaro Tomida, Takeshi Kageyama, Junya Furukawa, Hiroomi Kanayama, Hisanori Uehara","doi":"10.1007/s13691-026-00864-4","DOIUrl":"10.1007/s13691-026-00864-4","url":null,"abstract":"<p><p>We report a rare case of adenocarcinoma with endometrioid features in an 80-year-old male with a history of long-term hormonal therapy for prostate cancer. Over a 13-year course of estrogen therapy, multiple lesions developed sequentially, beginning approximately three years after treatment initiation. These lesions involved the left vas deferens, prostatic urethra, and left pelvic-to-inguinal region. Histologically, the prostatic lesion showed adenocarcinoma with endometrioid features, whereas the other lesions demonstrated features reminiscent of atypical endometrial hyperplasia or an ovarian-type endometrioid borderline tumor. Notably, all specimens showed a consistent immunoprofile characterized by positivity for PAX8, ER, PgR, and negativity for NKX3.1, supporting a Müllerian origin. Although previous reports have suggested an association between endometrioid tumors and estrogen therapy for prostate cancer, this case is distinctive in that sustained tumor regression and long-term survival were achieved solely through discontinuation of estrogen therapy. The clinical course and anatomical distribution of the lesions suggest a possibility of multicentric development from Müllerian remnants under prolonged hormonal stimulation.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"15 3","pages":"354-361"},"PeriodicalIF":0.4,"publicationDate":"2026-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13376113/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148578510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular pathology provides significant insights into the diagnosis and treatment of cancer of unknown primary origin: a case report of an extremely rare male occult breast apocrine cancer.","authors":"Yusuke Hayashi, Taichi Yoshida, Koji Fukuda, Kazuhiro Shimazu, Daiki Taguchi, Naoaki Kodama, Tomohiro Matsumoto, Anna Terasawa, Eriko Takahashi, Yuko Hiroshima, Kazuhiro Imai, Hiroshi Nanjyo, Hiroyuki Shibata","doi":"10.1007/s13691-025-00840-4","DOIUrl":"10.1007/s13691-025-00840-4","url":null,"abstract":"<p><p>We present a case of occult apocrine breast cancer in a man presenting with back pain and multiple bone and large liver metastases. The primary tumour was not identified, and the patient was initially considered to have cancer of unknown primary origin. During referral to our hospital, 2 months had passed since the initial consultation, and the prognosis was considered poor. Empirical treatment with carboplatin and paclitaxel was then administered. Histological examination of the liver metastases revealed large cells with eosinophilic cytoplasm, morphologically suggestive of apocrine breast cancer, but no tumour was found in the breast. The diagnosis of occult apocrine breast cancer was confirmed by concurrent immunohistochemical examination of the biopsy tissue sample, revealing androgen receptor positivity, oestrogen receptor negativity, gross cystic disease fluid protein 15 positivity, human epidermal growth factor receptor 2 overexpression, and gene amplification. Carboplatin and paclitaxel treatment resulted in the near-complete remission of liver metastases and reduction of bone metastases. The reduction has still been maintained at 16 months since the symptom onset. Molecular targeted therapy, including trastuzumab, is expected to further extend survival. Male occult apocrine breast cancer is extremely rare, with only one other case reported in the literature. We report the diagnosis and treatment response of this extremely rare case.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"15 3","pages":"295-300"},"PeriodicalIF":0.4,"publicationDate":"2026-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13376071/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148578481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Two successful deliveries following fertility-sparing treatment for synchronous endometrial and ovarian cancer: a case report and literature review.","authors":"Mamiko Ohta, Kosuke Murakami, Kazuyoshi Kato, Noriomi Matsumura","doi":"10.1007/s13691-026-00867-1","DOIUrl":"10.1007/s13691-026-00867-1","url":null,"abstract":"<p><p>Fertility-sparing treatment is a viable treatment option for selected patients with endometrial or ovarian cancer. However, its use in synchronous endometrial and ovarian cancer (SEOC) remains rare, and standardized treatment strategies have yet to be established. We report the case of a 26-year-old woman diagnosed with SEOC, characterized as grade 1, stage IA endometrioid carcinoma of both the endometrium and ovary. Genetic analysis ruled out hereditary cancer syndromes, including Lynch syndrome. The patient was treated with medroxyprogesterone acetate for 26 weeks, after which histological evaluation confirmed complete remission. She subsequently achieved two spontaneous pregnancies, both resulting in uncomplicated vaginal deliveries. To our knowledge, this is the fifth reported case of childbirth following fertility-sparing treatment for SEOC and the first involving two successful deliveries.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"15 3","pages":"375-380"},"PeriodicalIF":0.4,"publicationDate":"2026-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13375991/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148578637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}